Launched Serif Biomedicines with $50M in founding capital to develop modified DNA genetic medicines.
Serif Biomedicines is pioneering a new category of biotechnology to treat and prevent disease by using a novel approach to program how nucleic acids behave inside the body, enabling DNA to be used as medicine for the first time
Serif Biomedicines is pioneering a new category of biotechnology to treat and prevent disease by using a novel approach to program how nucleic acids behave inside the body, enabling DNA to be used as medicine for the first time.